Journals | Policy | Permission

Journal of Neurology Research

Case Report

Volume 10, Number 6, December 2020, pages 235-236

Facial Diplegia as a Rare Late Neurologic Manifestation of SARS-CoV-2 Infection

Neurological manifestations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are rare. Among these are encephalitis, anosmia and ageusia, acute cerebrovascular disease including ischemic stroke, and Guillain-Barre syndrome (GBS) and its variants. Facial diplegia (FD) is a rarely reported late neurologic complication of this novel virus. We report a case of a patient who presented with FD approximately 3 weeks following confirmed SARS-CoV-2 infection.

A 64-year-old man initially presented to an outpatient clinic with complaints of cough, fever, and chills for 1 week. A SARS-CoV-2 polymerase chain reaction (PCR) test was positive, and the patient was advised to self-quarantine. He recovered completely from the respiratory symptoms. Approximately 3 weeks following the onset of respiratory symptoms, he presented to the emergency department with complaints of progressive bilateral facial weakness, dysarthria, and subjective facial paresthesia for the previous 2 days. On examination, he was observed to have bilateral facial nerve palsy in a peripheral distribution, more pronounced on the right. The remaining cranial nerves appeared normal. Motor, sensory, coordination, and gait examination was unremarkable.

Repeat SARS-CoV-2 PCR was negative. Magnetic resonance imaging of the brain with and without gadolinium was unremarkable for any acute pathology. Cerebrospinal fluid (CSF) analysis revealed lymphocytic pleocytosis of 10 white blood cells (WBCs)/mm³ (100% lymphocytes), mild elevation of protein level at 53 mg/dL, and normal glucose at 66 mg/dL. Lyme serologies revealed elevation in immunoglobulin M (IgM) antibody index at 1.57 (reference range < 0.91) but confirmatory Western blot was negative. Lyme CSF antibody index was negative. Additional infectious workup including cytomegalovirus (CMV) and human T-lymphotropic virus was negative. Remaining neurologic workup including acetylcholine receptor antibodies (binding, blocking, modulating), muscle-specific tyrosine kinase (MuSK) antibody, ganglioside antibodies (including anti-GQ1b), serum angiotensin converting enzyme level was unremarkable. Patient was ultimately discharged in a stable condition with gradual improvement of the facial weakness and paresthesia.

Multiple neurologic complications of the SARS-CoV-2 infection have been identified. Possible mechanisms of neurologic injury include direct neurotropism, which has been postulated to be the mechanism underlying anosmia/ageusia and encephalitis, systemic inflammatory responses resulting in hypoxic or toxic-metabolic nervous system injury, or a delayed onset autoimmune-mediated mechanism. While GBS is known to be a parainfectious complication of multiple viruses including influenza, Zika virus, and CMV, to our knowledge, less than 15 reports of delayed onset SARS-CoV-2 related Guillain-Barre-like complications have been identified [1]. The majority of cases describe acute onset of para- or tetraplegia in the setting of known SARS-CoV-2 infection [2-4]. In reported cases, a 2 - 3 week latent period from time of infection to neurologic symptom onset was observed, which may suggest an autoimmune etiology [3, 4]. In contrast to our case, CSF analysis did not reveal pleocytosis or increased protein level [2-4]. Only one other case of FD related to SARS-CoV-2 has been reported [5], with mild elevation of CSF protein level at 44 mg/dL. Our case report is in concordance with previous literature reporting an association of FD variant GBS with negative ganglioside antibodies [6].

A growing amount of evidence suggests that SARS-CoV-2 has a multitude of neurologic manifestations. To our knowledge, our case is only the second reported case of FD following a SARS-CoV-2 infection. Patients presenting with symptoms suggestive of acute neurologic disorders should be evaluated carefully regarding recent infectious symptoms or possible exposures to help identify and minimize late complications of this novel virus.

Acknowledgments

None to declare.

Financial Disclosure

No funding was received. None of the authors have disclosures relevant to this manuscript.

Conflict of Interest

None to declare.

Informed Consent

Not applicable.

Author Contributions

All authors participated in data collection, data interpretation and editing the manuscript.

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

1. Gutierrez-Ortiz C, Mendez-Guerrero A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Manas R, de Aragon-Gomez F, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5):e601-e605.
   doi pubmed
2. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383-384.
   doi
3. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020;76:233-235.
   doi pubmed
4. Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barre syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. J Peripher Nerv Syst. 2020;25(2):204-207.
   doi pubmed
5. Juliao Caamano DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barre Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020;77:230-232.
   doi pubmed
6. Kim JK, Oh SY, Sohn EH, Hong YH, Jun SM, Bae JS. When is facial diplegia regarded as a variant of Guillain-Barre syndrome? J Peripher Nerv Syst. 2015;20(1):32-36.
   doi pubmed

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Neurology Research is published by Elmer Press Inc.